BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Bibliographic Details
Main Authors:	Zepeda-Lopez, Priscilla Denise, Salas-Alanis, Julio Cesar, Toussaint-Caire, Sonia, Gutierrez-Mendoza, Daniela, Vega-Memije, Elisa, Silva, Saúl Lino, Fajardo-Ramírez, Oscar Raul, Alcazar, Gregorio, Moreno-Treviño, María Guadalupe, Saldaña, Hugo Alberto Barrera
Format:	Online
Language:	English
Published:	S. Karger AG 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868925/

Similar Items

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
by: Wilmott, J S, et al.
Published: (2013)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
by: Zaharie, Florin, et al.
Published: (2015)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

BRAF V600E-Negative Hairy Cell Leukaemia
by: Langabeer, Stephen E., et al.
Published: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
by: HE, GUOPING, et al.
Published: (2014)

Amelanotic melanoma presenting with plasmacytoid morphology and BRAF V600 mutation
by: Linda Kocovski, et al.
Published: (2015-06-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi, Maria, et al.
Published: (2016)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
by: Park, Charny, et al.
Published: (2015)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
by: Levinsohn, Jonathan L., et al.
Published: (2015)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
by: Simpson, Dennis A., et al.
Published: (2015)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
by: Kocovski, Linda, et al.
Published: (2015)

High frequency of BRAF V600E mutations in ameloblastoma
by: Kurppa, Kari J, et al.
Published: (2014)

BRAF V600 mutations and pathological features in Japanese melanoma patients
by: Yamazaki, Naoya, et al.
Published: (2015)

Adult classical glioblastoma with a BRAF V600E mutation
by: Takahashi, Yoshinobu, et al.
Published: (2015)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
by: Robinson, Giles W, et al.
Published: (2014)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
by: Fedorenko, Inna V., et al.
Published: (2015)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
by: Ahn, Jun-Ho, et al.
Published: (2015)

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
by: Rustad, E H, et al.
Published: (2015)

Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting
by: Mourah, Samia, et al.
Published: (2015)

Essays on Mexican migrants' remittances
by: Saldaña Hernández, Miriam
Published: (2018)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
by: Ponti, Giovanni, et al.
Published: (2012)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
by: Tahiri, Andliena, et al.
Published: (2013)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
by: Roller, Devin G., et al.
Published: (2015)

Pemphigus Foliaceus in an 11-Year-Old Mexican Girl with Response to Oral Dapsone
by: García-Meléndez, Martha Elena, et al.
Published: (2013)

The Mexican Pension Annuity Market
by: Impavido, Gregorio
Published: (2012)

Gender-Dependent Association of FTO Polymorphisms with Body Mass Index in Mexicans
by: Saldaña-Alvarez, Yolanda, et al.
Published: (2016)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
by: Sigalotti, L, et al.
Published: (2011)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
by: Poulikakos, Poulikos I., et al.
Published: (2011)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
by: Rowe, Leslie R, et al.
Published: (2006)

A Micro-RNA Connection in BRaf V600E-Mediated Premature Senescence of Human Melanocytes
by: Ren, Gang, et al.
Published: (2012)

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
by: Dias-Santagata, Dora, et al.
Published: (2011)

A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
by: Rad, Roland, et al.
Published: (2013)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
by: Kang, So Young, et al.
Published: (2013)

Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR
by: Huang, Tiangui, et al.
Published: (2013)

BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
by: Bates, Sara V., et al.
Published: (2013)

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
by: Hu, W, et al.
Published: (2013)

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600
by: Skorokhod, Alexander, et al.
Published: (2013)

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
by: Ida, Cristiane M, et al.
Published: (2013)

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
by: Berres, Marie-Luise, et al.
Published: (2014)